3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Conditions
Ovarian Neoplasms
1
Metastatic Castration Resistant Prostate Cancer
1
Fallopian Tube Neoplasms
1
Interventions
Carboplatin
36
Cisplatin
32
pembrolizumab
30
Paclitaxel
29
Pemetrexed
22
Gemcitabine
21
Nivolumab
19
Dexamethasone
17
Rituximab
16
Fluorouracil
13
Docetaxel
13
durvalumab
12
Ipilimumab
12
Capecitabine
12
Cyclophosphamide
11
atezolizumab
10
130-nm albumin-bound paclitaxel
10
olaparib
9
Trastuzumab
9
Lenalidomide
9
Doxorubicin
9
Cytarabine
9
Bevacizumab
9
daratumumab
8
Oxaliplatin
8
Bortezomib
8
Vinorelbine
7
Prednisone
7
Leucovorin
7
venetoclax
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Has announcements
×
rucaparib
×
Clear all
NCT02975934
2025-07-25
TRITON3
pharmaand GmbH
Phase 3
Completed
405 enrolled
34 charts
1 FDA
NCT01968213
2023-06-09
ARIEL3
pharmaand GmbH
Phase 3
Completed
564 enrolled
18 charts
1 FDA